21 results
PRE 14A
GLTO
Galecto Inc
16 Apr 24
Preliminary proxy
4:00pm
with the engagement. Campaign Management may solicit proxies by mail, telephone, facsimile or e-mail.
Will my shares be voted if I do not return my proxy … submission by employees of concerns regarding questionable accounting, internal accounting controls or auditing matters.
Stockholder Engagement
Senior
8-K
GLTO
Galecto Inc
21 Dec 23
Other Events
4:30pm
target engagement systemically by binding to lysyl oxidase-like 2 (LOXL2) in plasma.
All six patients who experienced a 1-grade reduction in bone
8-K
EX-99.1
GLTO
Galecto Inc
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
there was no confirmation of target engagement in the trial. The mean change in FVC from baseline to week 52 was -316.6 ml in the GB0139 3 mg arm
8-K
nas25uxzw3rru8wc2
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
EX-99.1
dad2alqpi46t bs44
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
EX-99.1
35xc3
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
EX-99.1
5hxkrmui31wuymn
5 Jan 22
Regulation FD Disclosure
4:02pm
DEF 14A
97xatwv
14 Apr 21
Definitive proxy
7:00am
10-K
yro030zpy67apmbxf
29 Mar 21
Annual report
6:03am
8-K
EX-99.1
6qj9dp92mb 4grfol
5 Jan 21
Results of Operations and Financial Condition
4:31pm
S-1/A
EX-10.4
xmav64u9b9xj
22 Oct 20
IPO registration (amended)
6:13am